Drug Trial Radar · NCT07097935
Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Jul 10, 2027
Study completion Jul 10, 2028
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase Ib/II clinical study evaluating the safety, efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profiles of HS-10516 in combination with lenvatinib in patients with advanced clear cell renal cell carcinoma (ccRCC) who have progressed after receiving at least one prior line of systemic therapy. The study comprises two distinct phases: a dose exploration phase and a proof-of-concept phase.
Conditions
- Advanced Clear Cell Renal Cell Carcinoma
Interventions
HS-10516 + LenvatinibDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: MTD or RP2DTime frame: Up to 3 months
- Phase II: Objective Response Rate (ORR)Time frame: Up to 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.